Single Use Support Further Expands Into US Market
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical industry, is excited to announce...
Pharmaceutical
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent...
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We”...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024ENCINITAS, Calif., June 14, 2023 (GLOBE...
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a...
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and...
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at...
SmithRx will be First PBM to Offer YUSIMRY, a Humira Biosimilar, for One-Tenth the List Price of Humira
Teaming up with Mark Cuban Cost Plus Drug Company, SmithRx will start offering members access beginning in July 2023SAN FRANCISCO,...
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023...
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Longeveron Welcomes Three New Prominent Board Members
Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of...